IRF5 peptide inhibitor

IRF5 peptide inhibitor refers to a class of research-stage peptide-based compounds designed to selectively inhibit Interferon Regulatory Factor 5 (IRF5), a transcription factor that acts as a master switch for proinflammatory versus anti-inflammatory responses. The most characterized variant, N5-1 (amino acid sequence: PRRVRLK), is a cell-permeable peptide mimetic that binds to and stabilizes the inactive IRF5 monomer with high affinity (KD = 98.8 nM). This stabilization prevents IRF5 from forming active dimers and translocating to the nucleus, thereby inhibiting the expression of downstream inflammatory cytokines. Developed primarily at the Feinstein Institute for Medical Research, these inhibitors have demonstrated therapeutic potential in preclinical models of systemic lupus erythematosus (SLE), myocardial inflammation, and fibrosis by reducing autoantibody levels and ameliorating disease severity.

Other names

IRF5 inhibitor N5-1IRF-5 inhibitor N5-1IRF 5 inhibitor N5-1IRF5 decoy peptideIRF-5 decoy peptideIRF 5 decoy peptidePRRVRLK